ROVIELLO, GIANDOMENICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.702
AS - Asia 10.615
EU - Europa 8.499
SA - Sud America 2.383
AF - Africa 210
OC - Oceania 144
Continente sconosciuto - Info sul continente non disponibili 5
Totale 36.558
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.517
RU - Federazione Russa 4.060
CN - Cina 3.195
SG - Singapore 2.794
BR - Brasile 1.944
HK - Hong Kong 1.471
IT - Italia 1.271
KR - Corea 1.263
VN - Vietnam 892
PL - Polonia 870
IE - Irlanda 744
SE - Svezia 323
IN - India 289
FI - Finlandia 266
DE - Germania 254
ID - Indonesia 204
AR - Argentina 173
GB - Regno Unito 159
AU - Australia 140
FR - Francia 134
EC - Ecuador 98
JO - Giordania 94
ES - Italia 84
BD - Bangladesh 82
NL - Olanda 75
TR - Turchia 68
CA - Canada 65
CH - Svizzera 64
MX - Messico 61
JP - Giappone 51
AT - Austria 48
ZA - Sudafrica 48
CI - Costa d'Avorio 39
CO - Colombia 39
IQ - Iraq 38
UA - Ucraina 37
BJ - Benin 33
PY - Paraguay 30
MA - Marocco 28
CL - Cile 25
PE - Perù 25
EG - Egitto 24
VE - Venezuela 23
UZ - Uzbekistan 22
PK - Pakistan 21
AE - Emirati Arabi Uniti 20
LU - Lussemburgo 19
UY - Uruguay 16
BE - Belgio 15
SA - Arabia Saudita 14
CZ - Repubblica Ceca 12
KZ - Kazakistan 12
AZ - Azerbaigian 11
DO - Repubblica Dominicana 11
RS - Serbia 11
BO - Bolivia 10
HN - Honduras 10
KE - Kenya 10
PT - Portogallo 9
TN - Tunisia 9
NI - Nicaragua 8
NP - Nepal 8
GR - Grecia 7
IL - Israele 7
LT - Lituania 7
MY - Malesia 7
TT - Trinidad e Tobago 7
DZ - Algeria 6
PH - Filippine 6
BB - Barbados 5
JM - Giamaica 5
KG - Kirghizistan 5
NO - Norvegia 5
OM - Oman 5
TH - Thailandia 5
BY - Bielorussia 4
GT - Guatemala 4
AL - Albania 3
BH - Bahrain 3
GE - Georgia 3
HU - Ungheria 3
IR - Iran 3
KH - Cambogia 3
KW - Kuwait 3
LB - Libano 3
NZ - Nuova Zelanda 3
PA - Panama 3
RO - Romania 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BG - Bulgaria 2
CR - Costa Rica 2
CY - Cipro 2
LK - Sri Lanka 2
LV - Lettonia 2
MD - Moldavia 2
NG - Nigeria 2
PS - Palestinian Territory 2
SV - El Salvador 2
Totale 36.534
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.517
Singapore 2.175
Ashburn 1.597
Fairfield 1.595
Hefei 1.382
Hong Kong 1.271
Seoul 1.262
Warsaw 862
Dublin 739
Woodbridge 734
Seattle 682
Houston 584
Cambridge 565
Wilmington 524
Beijing 477
Lawrence 334
San Jose 334
Altamura 332
Ho Chi Minh City 323
Moscow 310
Los Angeles 238
Ann Arbor 203
Buffalo 202
Chandler 199
Florence 184
Princeton 171
Boston 170
São Paulo 160
Helsinki 157
Hanoi 151
Kent 150
Jakarta 141
Dallas 140
Clifton 133
Melbourne 129
The Dalles 126
Mumbai 119
Munich 108
New York 100
Shanghai 82
San Diego 80
Bengaluru 78
Rome 76
Lappeenranta 70
Milan 69
Barcelona 57
Bern 57
London 57
Rio de Janeiro 52
Boardman 51
Paris 51
Redondo Beach 47
Dong Ket 46
Brasília 43
Haiphong 42
Bremen 41
Chicago 40
Abidjan 39
Medford 39
Curitiba 38
Frankfurt am Main 38
Vienna 38
Guayaquil 37
Norwalk 37
Turku 37
Tokyo 35
Cotonou 33
Porto Alegre 31
West Jordan 31
Falls Church 29
Belo Horizonte 28
Da Nang 27
Johannesburg 27
Biên Hòa 26
Buenos Aires 26
Quito 26
Pune 25
Yubileyny 25
Brooklyn 24
Toronto 24
Stockholm 23
Ninh Bình 21
Phoenix 21
Adana 20
Arezzo 20
Montreal 20
Campinas 19
Denver 19
Guarulhos 19
Thái Bình 19
Hải Dương 18
Lima 18
Tashkent 18
Chennai 17
Fortaleza 17
Mexico City 17
Shenzhen 17
Dhaka 16
Hillsboro 16
Poplar 16
Totale 24.710
Salva come PNG Salva come JPEG
Nome #
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience 278
Darolutamide in hormone-sensitive and castration-resistant prostate cancer 242
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 214
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 212
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 202
A husband and a wife with simultaneous presentation of glioblastoma multiforme: a case report 201
Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer 189
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 186
An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer 186
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 186
Is there still a place for docetaxel rechallenge in prostate cancer? 185
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 184
Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer 180
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study 180
Current status and future perspectives in HER2 positive advanced gastric cancer 178
Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer 177
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 176
Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope? 172
Isolated Testicular Metastasis from Prostate Cancer 172
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 172
Gender and Advanced Urothelial Cancer: Outcome, Efficacy and Toxicity following Chemotherapy 169
Adjuvant treatment for EGFR-mutated non-small cell lung cancer: Do we have a major breakthrough? 169
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience 168
Ntrk gene fusion detection in atypical spitz tumors 168
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015 164
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer 164
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223 163
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin 163
A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial 160
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors 159
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer 159
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now? 159
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 159
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033 158
Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer? 158
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 158
Inflammation in Urological Malignancies: The Silent Killer 157
Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer 157
Robotic approach with neoadjuvant chemotherapy in adult Wilms' tumor: A feasibility study report and a systematic review of the literature 156
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI 155
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 154
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 154
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 154
DNA repair deficiency as circulating biomarker in prostate cancer 153
Immune checkpoint inhibitor-induced neurologic toxicity: a case report and literature review 152
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 152
Gender and cystectomy for bladder cancer: A high-volume tertiary urologic care center experience 150
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 150
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival 150
Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status 147
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 147
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 146
NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities 145
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer 145
Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights 145
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer 145
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 145
The distinctive nature of adenocarcinoma of the lung 145
Perineural invasion score system and clinical outcomes in resected pancreatic cancer patients 144
Advances in systemic therapy for metastatic breast cancer: future perspectives 144
Bevacizumab in small cell lung cancer 143
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25) 142
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate 142
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 141
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment 140
Targeting z-Crystallin by aspirin restores the sensitivity to cisplatin in resistant A2780 ovarian cancer cells 139
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 139
Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14) 139
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors 138
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies 138
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study 138
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 137
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 137
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? 136
Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis 136
Editorial: Microbiota and metabolites in cancer immunotherapy 135
New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials 135
Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer 135
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 135
Acute Massive and Submassive Pulmonary Embolism: Preliminary Validation of Aspiration Mechanical Thrombectomy in Patients with Contraindications to Thrombolysis 135
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study 135
Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma 134
Role of ATP-binding cassette transporters in cancer initiation and progression 133
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC) 133
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? 133
ALTERTASTE: improving food pleasure and intake of oncology patients receiving chemotherapy 133
Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19) 133
Second line of treatment for HER2-positive gastric cancer: an evolving issue 132
Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis 132
Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence 132
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 132
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials 131
Immune checkpoint inhibitors in urothelial bladder cancer: State of the art and future perspectives 131
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study 130
Immunotherapy-based combinations versus standard first-line and hypothyroidism risk 130
In reply to Egger et al.: Lack of benefit from adjuvant postoperative radiotherapy and issues raised about upfront management of high- and very-high-risk prostate cancer patients 130
Surgical management of advanced gastric cancer: An evolving issue 130
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group 129
Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy 129
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development 129
Totale 15.453
Salva come PNG Salva come JPEG
Categoria #
all - tutte 115.370
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.370
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021990 0 0 0 0 0 0 98 73 313 164 222 120
2021/20221.018 9 11 96 29 29 107 11 137 87 38 107 357
2022/20232.731 269 770 69 162 36 447 491 110 179 51 53 94
2023/20241.637 49 90 273 79 102 162 56 299 62 219 117 129
2024/202512.158 481 1.276 692 1.629 3.083 1.541 316 391 898 403 563 885
2025/202612.940 1.747 2.724 2.828 2.936 1.611 548 546 0 0 0 0 0
Totale 37.013